GREENVILLE, S.C., March 13 /PRNewswire-FirstCall/ -- Signalife, Inc. , a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring, today announced that it is exhibiting its products at the 55th Annual Scientific Session hosted by the American College of Cardiology in Atlanta, GA from March 11-13th.
The mission of the American College of Cardiology is to advocate for quality cardiovascular care through education and research and development. The American College of Cardiology represents the majority of U.S. cardiovascular physicians.
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company's website is available at: http://www.signalife.com/.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife, Inc. results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approval governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife's products or services, adverse equity market conditions and declines in the value of Signalife's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
